LUNGevity Foundation names Sam Rogers chief development officer. September 16, 2026 Sam Rogers LUNGevity Foundation has appointed Sam Rogers as chief development officer, bringing in a veteran cancer philanthropy executive to lead its fundraising strategy as the organization seeks to increase investment across lung cancer research, patient support and advocacy. Rogers brings nearly two decades of nonprofit fundraising and cancer philanthropy experience to the role. He will oversee LUNGevity's development strategy, with responsibility for expanding and diversifying philanthropic support while building on the foundation's existing donor and partner relationships. The appointment comes at a consequential period for lung cancer research and care. Advances in early detection, precision medicine and treatment are creating new opportunities for patients, while translating those developments into broader clinical impact requires sustained funding for research, trials, patient services and access initiatives. "Driving meaningful change in lung cancer requires bold ideas, strong partnerships, and the resources to turn possibility into progress," said Andrea Ferris, president and CEO of LUNGevity Foundation. Ferris said strengthening the organization's development leadership is intended both to deepen relationships with its existing philanthropic community and create new partnerships. Rogers' experience connecting donors with cancer-focused programs is expected to support LUNGevity's efforts to finance a broader range of initiatives. His mandate spans the lung cancer continuum. LUNGevity said Rogers will work to increase sustainable funding for early detection and precision medicine, research programs, clinical trial access, survivorship initiatives and public policy advocacy, as well as information and support services for patients and families. The role places fundraising strategy at the intersection of scientific progress and commercialization and access challenges in cancer care. New diagnostics and therapies can expand treatment options, but their impact depends partly on whether research can advance, clinical trials can recruit appropriate patients and people diagnosed with lung cancer can access testing, treatment and reliable information. "There has never been a more important time to invest in lung cancer," Rogers said. "Scientific advances are creating opportunities that would have been unimaginable not long ago, but realizing their full potential requires sustained investment." Rogers joins LUNGevity after four years in senior leadership at the American Association for Cancer Research Foundation, where he worked on philanthropic strategy and developing pathways for sustainable fundraising growth. Earlier, he spent more than eight years with the Lymphoma Research Foundation. His responsibilities there extended across multiple fundraising channels as well as marketing and patient communications, giving him experience with both donor development and engagement with cancer patient communities. Rogers holds a Master of Science and a bachelor's degree from The New School. At LUNGevity, he joins an organization that operates across research funding, advocacy and patient support rather than concentrating on a single component of the lung cancer ecosystem. The foundation describes itself as the largest nonprofit funder of lung cancer research in the United States, with programs covering early detection, treatment development and support for emerging researchers. Its work also includes providing scientifically reviewed information and resources to patients and caregivers and advocating for access to lung cancer screening, biomarker testing, treatment and care. The fundraising push comes against the scale of the disease in the U.S. LUNGevity estimates that more than 229,000 Americans will be diagnosed with lung cancer this year. The foundation also reports a five-year survival rate of 28% across all lung cancer diagnoses, compared with 65% when the disease is detected before it spreads. Rogers' appointment positions development strategy as a key component of LUNGevity's next stage of growth, with the foundation seeking to translate philanthropic capital into research progress, stronger patient access and sustained support across the lung cancer care continuum.

Harmonizing data collection for precision oncology: AACR Project GENIE(R) Data Model. Precision oncology relies on large amounts of data, often combining multiple datasets from different institutions, to produce reliable, representative, and clinically meaningful results to guide cancer prevention, diagnosis, and treatment. Despite standardization efforts, inconsistencies in the practices of data capturing, definition, and storage persist and represent a big challenge for researchers. In an attempt to simplify data harmonization, the AACR Project GENIE(R)(Genomics Evidence Neoplasia Information Exchange) consortium created a new data model, called GENIE Data Model (GDM), an open-access framework that helps standardize longitudinal clinical and genomic data collection across solid tumors at different stages of a patient's cancer journey from diagnosis through long-term outcomes. GDM, which was the result of a collaboration among subject matter experts from academia and the government and included the patient advocate perspective, was released publicly on April 28 and presented during a Methods Workshop at the AACR Annual Meeting 2026. The model was also described in a paper published in Cancer Research Communications. What is a Data Model? A data model is a blueprint that defines what data will be collected, how the data will be organized, and the rules for storing and using the information in a consistent way. "There is a lot of clinical information that can be repurposed from study to study," said Jennifer Hoppe, MPH, a senior clinical project manager at Project GENIE and the first author of the paper. "Suppose you are an academic team that is conducting a research project for which you need to collect patient data across different clinical studies, such as demographics, cancer diagnosis, what drugs the patients received, and when their treatment started and ended. Rather than the researchers having to build a model for how they collect all this information for every single study, we have done that work in advance and built a model every research team can directly use to start entering data right away. I think most researchers would find this work really helpful." Why a new model? "Many data models already exist, each with its own complexity and built with a specific purpose in mind," said Hoppe. "The GDM was built to be applicable to many different solid tumors and different use cases while aligned to currently used standards." During the Annual Meeting session, chair Jeremy L. Warner, MD, a professor of medicine at Brown University, who was one of the co-lead principal investigators on the GDM project, discussed the importance of data harmonization. He pointed out that oncology data, particularly real-world data, are still fragmented, with incompatible electronic health records, mismatches and different nomenclatures in genomic annotations, inconsistently recorded outcomes, and a lack of granular longitudinal data. The GDM was created with these challenges in mind. It was designed as a modular, tumor-agnostic core, into which disease-specific extensions can be plugged in as needed, and to be extensible and scalable in the future, Warner said. He emphasized that the GDM model is about breaking down data silos and enabling a connected ecosystem for oncology research. The work to develop the GDM builds on more than a decade of experience of the Project GENIE consortium in assembling and growing the Project GENIE registry of real-world genomic data through data sharing among 20 leading international cancer centers. "The GDM was specifically designed to facilitate the collection of more key clinical variables programmatically, allowing GENIE to get closer to our goal of documenting complete patient cancer experiences for every patient in the registry," said Shawn M. Sweeney, PhD, senior director of the AACR Project GENIE Coordinating Center. "Ultimately, the GDM lays the foundation for fully federating the registry in the near future." Hoppe likened the registry to an iceberg. "What we have available is just the tip, but there is all that ice submerged still, all that information that exists on which we don't have visibility yet because we can't collect it," she said. "But as we deploy this model and we are able to collect more data, eventually we will see more and more of the full picture of that iceberg for all the patients in the GENIE registry." The development of the GENIE Data Model. The researchers reached out to members of the oncology community to assemble a team of 13 subject matter experts who were divided into four working groups. Hoppe explained that their first task was to establish which essential variables need to be collected to characterize a tumor exhaustively. These variables were organized into four content areas or clinical domains, spanning initial diagnosis through treatment and long-term outcomes, and each working group focused on its area of expertise: diagnosis, treatment, outcomes, or person-centered metrics, the latter including demographic variables, social determinants of health, and comorbidities. "Using their expert opinion, the working groups really helped shape what we would need to include so that the model is not composed of thousands of variables but encompasses the core group of variables that can give a reliable picture for almost any solid tumor," Hoppe explained. "We wanted the model to be widely applicable, but also specific enough to provide the information a researcher would need." Once the experts defined the variables and the corresponding parameters and value sets, the next step was to build that information into a database collection tool. Specifically, the team used REDCap (Research Electronic Data Capture), a specialized web-based software platform, but the GDM can be deployed within any data collection tool, added Hoppe. One important goal for the GDM was interoperability, a term that describes the ability of different information systems to communicate and exchange data seamlessly. In this case, each data variable in the GDM has a shared definition and parameters that are aligned to existing standards and terminologies and captured with the same value set. In addition, the GDM can work both with manually entered data and with data that have already been collected and stored in a structured way (for example, in Excel files or enterprise data warehouses), to minimize the curation effort. "Eventually, in the future, we would like to have 100% structured data supporting the Project GENIE registry, but since we are not there yet, we needed to develop something that was flexible enough to be able to incorporate both manually collected and structured data," said Hoppe. Deploying the model. The GDM is hosted in a repository on the cloud-based platform GitHub and can be accessed through a Creative Commons license. Researchers have access to three components: the database file, which can be loaded into REDCap or other data collection tools; an Excel file that contains the data dictionary, which provides an-easy-to-read overview of the variables and corresponding definitions and value sets; and a curation directives manual, or data completion guideline, which provides additional details to ensure homogenous use of the model across institutions. Limitations and what comes next. Since it was designed as a large pancancer model, GDM may not be entirely specific for each research project, said Hoppe. However, the team built it to be modifiable, so that the users can add additional fields as needed to accommodate their research questions. Another limitation is that the model is currently only suitable for solid tumors and cannot be utilized for studies on hematologic malignancies, she added. "We are working on an expansion that we will hopefully be able to deploy within the next year or two." The team is also developing packages of prebuilt algorithms to be applied by end users to perform calculations on the data collected by the model and obtain new, derived variables to create an analytic dataset. "For example, one could use a provided algorithm to calculate the duration of a treatment from the start and end dates of that treatment," said Hoppe. "The community can expect annual updates, and we hope end users will share any derivatives they create back with the broader research community so that we can all get to cures as quickly as possible," concluded Sweeney. AACR Annual Meeting sessions are available for virtual viewing for all registered attendees through October 2026.

Research Spotlight: highlights from the AACR Drug Discovery and Development conference. Share Tweet Editor's note: The "Research Spotlight" series is written by Dr. Anna Berkenblit, PanCAN's Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and research in pancreatic cancer. Follow Dr. Berkenblit on X and LinkedIn. I recently had the pleasure of attending the inaugural American Association for Cancer Research (AACR) Drug Discovery and Development (D3) conference. The meeting featured more than 600 participants, with invited speakers from academia, pharma, biotech, regulatory agencies and venture capital. It was a unique opportunity to have a collective conversation with all the stakeholders dedicated to moving the field forward. There were more than 200 poster presentations and over 80 oral presentations - it's clearly an exciting time for the field. The overarching message I took away from the conference was that Pancreatic Cancer Action Network, Inc. is all working together to streamline the drug development process to accelerate progress for patients. Drug development refers to the entire journey - from the identification of a target (molecule or mechanism) to production of an investigational drug that undergoes lab-based testing, initial studies in patients and, ultimately, clinical trials leading to potential drug approval. This process has historically been fraught with failure, extremely time-consuming, expensive and required many patients' participation. Some strategies that were discussed at the meeting to streamline the drug development process included centralizing the Institutional Review Board (IRB) or having one universal contract amongst all the clinical trial sites. The IRB serves to ensure that a clinical trial is designed to be safe and minimize risks to patient participation. Working through IRBs at multiple clinical trial sites can be cumbersome and redundant. Similarly, necessary contracting can be made more efficient if centralized among all the sites and stakeholders, rather than handled on a one-off basis. Having a centralized electronic medical record system can also help with storing and collecting data and minimizing redundancies when navigating multiple systems. Finally, there was discussion of better integration and partnership between the U.S. Food and Drug Administration (FDA) and academic sites. I hope that many of these ideas are realized in the near future, as the entire field of drug development for cancer stands to benefit from them. Turning now to what's exciting for pancreatic cancer specifically, I was interested to learn more about some new classes of drugs that are being developed against novel targets, including PRMT5, which may be a relevant target for up to 40% of pancreatic tumors. Previous efforts to target PRMT5 have involved cooperation with a molecule called SAM, but data showed that PRMT5-SAM inhibitors were not selective against cancer cells and therefore caused harm to healthy cells and led to toxicity. Researchers also discovered that the status of a gene known as MTAP could be used as a biomarker to predict responsiveness to PRMT5 inhibitors that cooperate with a molecule known as MTA. Data suggest that PRMT5-MTA cooperative drugs are effective and selective for cancer cells that have MTAP deletion - a phenomenon known as synthetic lethality when two conditions are necessary to kill the cancer cells. This helps spare healthy cells and reduces systemic toxicity. There were recent compelling data released about combining a PRMT5-MTA cooperative inhibitor known as vopimetostat with the RAS-targeting drug, daraxonrasib, in patients with previously treated metastatic pancreatic cancer. Although numbers were small and the trial was in an early phase, a response rate of 92% is definitely something to keep an eye on. Speaking of RAS inhibition, it was no surprise that RAS inhibitors were covered at the D3 conference. In addition to RASONQUE(TM)(daraxonrasib), which was approved by the FDA on August 26, 2026, for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy, there are nearly 100 investigational RAS-targeting drugs currently in various phases of clinical development. Some, like RASONQUE, target all activated RAS molecules, while others only target a specific mutation in a subset of RAS known as KRAS, which is mutated in more than 90% of pancreatic tumors. An excellent presentation by Dr. Ignacio Garrido-Laguna, who was featured in a recent PanCAN webinar, focused on redefining targeting RAS. Although a very new therapeutic approach, early learnings show mechanisms of resistance and clues about which patients' tumors would be most likely to respond. As these new RAS-targeting drugs are being developed, it's important to work in real time to learn which patients are most likely to benefit, devise novel combination strategies and determine ways to mitigate or prevent resistance. In fact, earlier this month, a new paper was published by scientists at Revolution Medicines, the company producing daraxonrasib, in collaboration with academic researchers to outline how cancer cells become resistant to RAS inhibition and potential ways to overcome that resistance. Pancreatic Cancer Action Network, Inc. anticipate learning more about adaptation mechanisms from the ongoing work that Break Through Cancer is doing through deep analysis of on-treatment biopsies from clinical trial participants with pancreatic cancer. It is admirable that this research is being done concurrently with clinical trials to support patients today and to pave the way for future innovations. It was clear from the AACR D3 meeting that stakeholders are passionately working toward more efficient systems and more effective and better tolerated therapies that patients deserve. It was exciting to be in the room at this inaugural and very successful conference. I have already started to take the learnings back to conversations within PanCAN and with its external partners that are part of the clinical trials ecosystem so that Pancreatic Cancer Action Network, Inc. can continue to accelerate progress for patients with pancreatic cancer. Donate today to support PanCAN's urgent efforts to improve outcomes for everyone affected by pancreatic cancer. Share Tweet You may also be interested in...